{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T21:06:38Z","timestamp":1762895198330,"version":"3.45.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":4682,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.fertnstert.2009.05.049","type":"journal-article","created":{"date-parts":[[2009,6,26]],"date-time":"2009-06-26T09:34:45Z","timestamp":1246008885000},"page":"403-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical assessment of fracture risk and novel therapeutic strategies to combat osteoporosis"],"prefix":"10.1016","volume":"92","author":[{"given":"Mark S.","family":"Nanes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caleb B.","family":"Kallen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2009.05.049_bib1","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.2106\/JBJS.G.00864","article-title":"Low incidence of anti-osteoporosis treatment after hip fracture","volume":"90","author":"Rabenda","year":"2008","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib2","first-page":"16","article-title":"Osteoporosis: an update","volume":"7","author":"Luciano","year":"2001","journal-title":"Hosp Phys Obstet Gynecol Board Rev Man"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib3","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1359\/jbmr.1997.12.11.1761","article-title":"Prevalence of low femoral bone density in older U.S. adults from NHANES III","volume":"12","author":"Looker","year":"1997","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bone.2003.10.001","article-title":"Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study","volume":"34","author":"Schuit","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib5","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1172\/JCI113523","article-title":"Age and bone mass as predictors of fracture in a prospective study","volume":"81","author":"Hui","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00198-008-0559-5","article-title":"Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA","volume":"19","author":"Dawson-Hughes","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00198-007-0550-6","article-title":"Cost-effective osteoporosis treatment thresholds: the United States perspective","volume":"19","author":"Tosteson","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","article-title":"Assessment of fracture risk","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/oxfordjournals.aje.a116314","article-title":"Risk factors for fractures of the distal forearm and proximal humerus. The Study of Osteoporotic Fractures Research Group","volume":"135","author":"Kelsey","year":"1992","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/gme.0b013e31817f3e4d","article-title":"A personal perspective on fracture risk assessment tools","volume":"15","author":"Ettinger","year":"2008","journal-title":"Menopause"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0002-9343(99)80080-1","article-title":"Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol","volume":"98","author":"Levy","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib12","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2002-020275","article-title":"Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women","volume":"87","author":"Tannenbaum","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib13","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/ajcn\/87.6.1945","article-title":"Effect of calcium supplementation on fracture risk: a double-blind randomized controlled trial","volume":"87","author":"Bischoff-Ferrari","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMoa055218","article-title":"Calcium plus vitamin D supplementation and the risk of fractures","volume":"354","author":"Jackson","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib15","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1001\/jama.293.18.2257","article-title":"Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials","volume":"293","author":"Bischoff-Ferrari","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0378-5122(03)00038-0","article-title":"Calcium-vitamin D3 supplementation is cost-effective in hip fractures prevention","volume":"44","author":"Lilliu","year":"2003","journal-title":"Maturitas"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0002-9343(99)80310-6","article-title":"Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial","volume":"98","author":"Reid","year":"1995","journal-title":"Am J Med"},{"issue":"Suppl 2","key":"10.1016\/j.fertnstert.2009.05.049_bib18","doi-asserted-by":"crossref","first-page":"V59","DOI":"10.1359\/jbmr.07s209","article-title":"Therapy of osteoporosis with calcium and vitamin D","volume":"22","author":"Dawson-Hughes","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib19","first-page":"424","article-title":"Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial","volume":"166","author":"Bischoff-Ferrari","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib20","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","article-title":"Mechanisms of anabolic therapies for osteoporosis","volume":"357","author":"Canalis","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib21","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib22","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib23","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/er.2001-9002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1185\/030079905X30752","article-title":"Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE","volume":"21","author":"Chesnut","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib27","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid in reducing clinical fracture and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib28","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib29","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib30","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension","volume":"19","author":"Ensrud","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib31","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib32","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw\u2014do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib33","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib34","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jama.1996.03540170033029","article-title":"Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen\/progestin interventions (PEPI) trial","volume":"276","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib36","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib37","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib38","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial","volume":"87","author":"Delmas","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib39","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","article-title":"Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study","volume":"20","author":"Siris","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib40","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib42","first-page":"267","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study","volume":"109","author":"Chesnut","year":"2000","journal-title":"PROOF Study Group. Am J Med"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib43","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib45","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib46","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.289.19.2525","article-title":"Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial","volume":"289","author":"Greenspan","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib47","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib48","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11154-006-9000-6","article-title":"Bone morphogenetic proteins and their antagonists","volume":"7","author":"Gazzerro","year":"2006","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib50","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2007-0036","article-title":"Growth hormone, insulin-like growth factors, and the skeleton","volume":"29","author":"Giustina","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib51","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/endo-124-1-301","article-title":"Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures","volume":"124","author":"McCarthy","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib52","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1210\/jc.2002-020656","article-title":"IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo","volume":"87","author":"Rubin","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib53","first-page":"3","article-title":"Signals that determine the fate of osteoblastic cells","volume":"28","author":"Canalis","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib54","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/ncb1647","article-title":"A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation","volume":"9","author":"Takada","year":"2007","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib55","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1172\/JCI28550","article-title":"Estrogen deficiency and bone loss: an inflammatory tale","volume":"116","author":"Weitzmann","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib56","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1196\/annals.1402.068","article-title":"T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis","volume":"1116","author":"Weitzmann","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib57","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jcb.240550309","article-title":"Cellular and clinical perspectives on skeletal insulin-like growth factor I","volume":"55","author":"Delany","year":"1994","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib58","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1242\/jcs.00623","article-title":"Secreted antagonists of the Wnt signalling pathway","volume":"116","author":"Kawano","year":"2003","journal-title":"J Cell Sci"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11154-006-9002-4","article-title":"Wnt signaling and osteoblastogenesis","volume":"7","author":"Bodine","year":"2006","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib60","doi-asserted-by":"crossref","first-page":"6203","DOI":"10.1074\/jbc.M508370200","article-title":"Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt\/beta-catenin but not bone morphogenetic protein signaling","volume":"281","author":"Deregowski","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib61","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1210\/endo.136.10.7664643","article-title":"Cortisol represses insulin-like growth factor II receptor transcription in skeletal cell cultures","volume":"136","author":"Rydziel","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib62","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib63","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib64","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib65","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib66","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.cell.2008.09.059","article-title":"Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum","volume":"135","author":"Yadav","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib67","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1172\/JCI113885","article-title":"Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures","volume":"83","author":"Canalis","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib68","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1210\/endo.142.10.8436","article-title":"Evidence that anabolic effects of PTH on bone require IGF-I in growing mice","volume":"142","author":"Miyakoshi","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib69","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1210\/endo.141.7.7585","article-title":"Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation","volume":"141","author":"Zhao","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib70","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1210\/jcem.87.6.8574","article-title":"Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa","volume":"87","author":"Grinspoon","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib71","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00198-007-0437-6","article-title":"Effects of treatment with fluoride on bone mineral density and fracture risk\u2014a meta-analysis","volume":"19","author":"Vestergaard","year":"2008","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.fertnstert.2009.05.049_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005326.pub2","article-title":"Strontium ranelate for preventing and treating postmenopausal osteoporosis","author":"O'Donnell","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib73","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1016\/j.fertnstert.2009.05.049_bib74","first-page":"iv20","article-title":"Strontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis","volume":"47","author":"Roux","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib75","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1359\/jbmr.060101","article-title":"Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors","volume":"21","author":"Roux","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.fertnstert.2009.05.049_bib76","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/sj.clpt.6100450","article-title":"Cathepsin K inhibitors: a novel target for osteoporosis therapy","volume":"83","author":"Stoch","year":"2008","journal-title":"Clin Pharmacol Ther"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028209012035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028209012035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T21:03:24Z","timestamp":1762895004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028209012035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0015028209012035"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2009.05.049","relation":{},"ISSN":["0015-0282"],"issn-type":[{"type":"print","value":"0015-0282"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical assessment of fracture risk and novel therapeutic strategies to combat osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2009.05.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}